KALV · KalVista Pharmaceuticals, Inc.

Current Thesis

KalVista Pharmaceuticals’ cash-acquisition thesis was settled by Chiesi’s 2026-06-11 completion announcement; reopening an equity thesis would require documented restoration of the original common stock. Chiesi reported that outstanding shares were cancelled and converted into rights to receive $27.00 per share, and that Nasdaq trading ceased. The narrative is dead — that classification follows the completed transaction, rather than an inference from weakening demand. Chiesi completion announcement.

The September 19 refresh leaves the September 5 conclusion intact. KalVista’s news-release index still ends with the 2026-06-11 acquisition announcement. That observable supports continuity of the published account, but does not establish that every subsequent legal or regulatory development has been excluded. KalVista news releases.

Bullish and bearish views on KalVista Pharmaceuticals, Inc.

The model's bull view on KalVista Pharmaceuticals, Inc. (KALV), in brief: The acquisition outcome was delivered. Chiesi’s 2026-06-11 announcement confirms completion of both the tender offer and subsequent merger. This is evidence that the former transaction thesis played out, rather than evidence of remaining equity appreciation. Completion… The bear view: The listed equity thesis ended. KalVista’s 2026-06-11 Form 8-K documents the merger and change of control. An operating-product thesis cannot alone establish a continuing claim through the former listed security. KalVista merger filing. Current positioning evidence is missing.… Both cases follow in full.

Bull Case

• The acquisition outcome was delivered. Chiesi’s 2026-06-11 announcement confirms completion of both the tender offer and subsequent merger. This is evidence that the former transaction thesis played out, rather than evidence of remaining equity appreciation. Completion announcement.
• The operating franchise continued elsewhere. Chiesi’s 2026-06-11 release identifies EKTERLY, the oral treatment for hereditary angioedema attacks, as an acquired product. Commercial progress belongs to the acquired business; it does not restore the cancelled common shares. Completion announcement.

Bear Case

• The listed equity thesis ended. KalVista’s 2026-06-11 Form 8-K documents the merger and change of control. An operating-product thesis cannot alone establish a continuing claim through the former listed security. KalVista merger filing.
• Current positioning evidence is missing. The supplied market observations end on 2026-06-10. No subsequent retail-flow, short-interest or insider-transaction dataset accompanies this refresh; there is insufficient evidence for a current crowding conclusion.

Setup & Price Structure

The supplied adjusted daily series records a final reference close of $27.00 on 2026-06-10, equal to its reported 52-week high. It also reports a three-month price increase of 55.4% and a 14-period relative strength index (RSI) of 77.1 as of that date. These are measured historical observations, not September momentum readings.

The inference is that those observations cannot establish an active breakout after the documented 2026-06-11 cessation of Nasdaq trading. The supplied data contain no moving-average level or subsequent daily bars. Consequently, neither a rising-average support claim nor expanding market participation is established. Merger filing.

Catalyst Calendar (next 30 days)

• ~2026-09-20, estimated administrative milestone. The September 5 published dossier identified this approximate registration-termination date following a reported 2026-06-22 Form 15-12G. Effectiveness has not been independently confirmed for this refresh, so the date remains provisional. It concerns registration status; the equity cancellation was already documented on 2026-06-11.

As of 2026-09-19, the reviewed evidence establishes no upcoming earnings, regulatory or transaction event that resolves a remaining KALV common-equity thesis. Accordingly, no prospective equity catalyst date is assigned.

What Would Change Our Mind

Restoration of the original common stock after a documented reversal of the merger would break the completed-transaction interpretation. The corresponding price condition would be a daily close below $27.00 in that restored security, referencing the supplied 2026-06-10 final close and the announced cash consideration. A quotation under a reused symbol would not establish restoration of the original claim.

The price condition is currently inoperative because the shares were cancelled in the 2026-06-11 merger. The conviction classification reflects an already documented transaction outcome; it does not represent a fresh forecast of appreciation before an active price threshold. Merger filing.

Correlation Notes

This remains a single-company transaction record. The supplied price series ends on 2026-06-10, and no paired return sample supports a claim about correlation with biotechnology equities, rare-disease developers or merger situations. Repeating the final quotation after the transaction would not supply new return observations. The evidence is insufficient for a correlation claim.